To systematically review the effectiveness and safety of modified Shenling Baizhu San in the treatment of ulcerative colitis (UC)

in order to provide a scientific basis for clinical promotion. Randomized clinical trials (RCT) for comparing the efficacy of Shenling Baizhu San with western medicines in treating ulcerative colitis were searched in CBM

CNKI

VIP and Wanfang databases. The studies were screened. The following data were extracted

such as effective rate

improvement time of main symptoms

endoscopic improvement and adverse events. The risk bias of included studies was assessed by the Cochrane scale. Meta-analysis was performed using RevMan 5.3 software. A total of 13 RCTs were eventually included. A total of 1 285 cases were included

including 659 cases in Shenling Baizhu San group and 598 in western medicine group. Compared with the western medicine group

the combined RR of the effective rate in the Shenling Baizhu San group was 1.17

(95%CI [1.13

1.22]

P<0.001)

the Shenling Baizhu powder group showed a shorter improvement time of diarrhea

abdominal pain

sepsis

and fever

with the effect size (RR=-12.32

95%CI[-14.27

-10.37]

P<0.001)

(RR=-8.06

95%CI[-9.88

-6.24]

P<0.001)

(RR=-9.89

95%CI[-10.77

-9.00]

P<0.001)

(RR=-8.29

95%CI[-9.59

-6.98]

P<0.001). The adverse events were statistically significant (RR=0.06

95%CI [0.01

0.40]

P=0.004). The endoscopic examination showed no significant difference. The effectiveness and safety of Shenling Baizhu San in the treatment of ulcerative colitis are more superior to western medicines

so it is suitable for clinical use. However

more large-sample-size double-blind RCTs shall be included to support this conclusion.